登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间： 2025年9月26日（星期五）上午9:00-10:00 ●会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心网络互动 ●投资者可于2025年9月19日(星期五)至9月25日(星期四)16:00前登录上证路演中心网站首页点击"提问预 征集"栏目或通过公司邮箱（ir@sxkh.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2025年半年度的经营成果及财务指标的具体情况与 投资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 1、会议召开时间： 2025年9月26日（星期五）上午9:00-10:00 2、会议召开地点：上海证券交易所上证路演中心（网址：http://roadsho ...

Core Viewpoint - The company, Shaanxi Kanghui Pharmaceutical Co., Ltd., is set to hold a half-year performance briefing on September 26, 2025, to discuss its operational results and financial status for the first half of 2025 [2][3]. Group 1: Meeting Details - The meeting will take place on September 26, 2025, from 9:00 AM to 10:00 AM [5]. - It will be conducted via the Shanghai Stock Exchange Roadshow Center, accessible online [4][5]. - Investors can participate by logging into the Roadshow Center during the meeting time [6]. Group 2: Investor Participation - Investors can submit questions for the briefing from September 19, 2025, to September 25, 2025, by visiting the "Pre-Question Collection" section on the Roadshow Center's website or via the company's email [6]. - The company will address commonly asked questions during the briefing [3][6]. Group 3: Contact Information - The company’s Securities Affairs Department can be contacted for inquiries via phone or email [6].

证券代码：603139 证券简称：康惠制药 公告编号：2025-061 陕西康惠制药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 19 日(星期五)至 9 月 25 日(星期四)16:00 前登 录 上 证 路 演中 心 网 站 首 页 点 击 " 提 问 预 征 集" 栏 目 或 通 过公 司 邮 箱 （ir@sxkh.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 陕西康惠制药股份有限公司（以下简称"公司"）已于 2025 年 8 月 27 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 9 ...

Group 1: Company Performance - Brothers Technology (002562) expects a net profit increase of 207%-253% for the first three quarters of 2025, with projected profits between 100 million to 115 million yuan, driven by rising prices of certain vitamin products and improved production capacity utilization [2] Group 2: Financing Activities - Vanke A has secured a loan of up to 2.064 billion yuan from its largest shareholder, Shenzhen Metro Group, to repay bond principal and interest, with the loan interest rate being lower than current market rates [3] - Hengwei Technology is planning to acquire 75% of Shanghai Shuhang Information Technology Co., with shares to be issued and cash payments involved, leading to a temporary suspension of trading starting September 17, 2025 [5] Group 3: Important Contracts - Jingzhida's subsidiary Hefei Integrated Circuit has signed a semiconductor testing equipment procurement agreement worth 323 million yuan, expected to positively impact the company's performance in 2025-2026 [7] - China Shipbuilding Technology has entered into a green methanol sales contract worth approximately 40 million USD per year, with potential increases based on customer demand, starting supply after the wind power methanol project is operational [7] Group 4: Shareholder Activities - Tianyu Co., Ltd. has seen its major shareholder release a pledge on 12.5 million shares, while still having 15.3 million shares pledged, representing 26.79% of the shareholder's total holdings [7] - Guotou Venture Capital plans to reduce its holdings by up to 9.186 million shares, representing 3% of the total share capital, citing personal funding needs [13]

Core Viewpoint - Several listed companies in the Shanghai and Shenzhen stock markets announced significant developments, including financing arrangements, asset sales, and strategic partnerships, which may present investment opportunities and risks for investors [4][5][6][8][9][10]. Financing and Borrowing - Vanke A announced that its largest shareholder, Shenzhen Metro Group, will provide a loan of up to 2.064 billion yuan to repay bond principal and interest, with a loan term of no more than three years and a floating interest rate based on the LPR minus 66 basis points [4]. - Jianfeng Group obtained a loan commitment of up to 36 million yuan from China Merchants Bank for stock repurchase, with a loan term of no more than 36 months at an interest rate of 1.8% [11]. Asset Sales and Acquisitions - Angli Education plans to sell 100% of Kensington Park School Limited for 80,000 pounds (approximately 760,100 yuan) to alleviate financial pressure [5]. - Guang'an Aizhong intends to acquire 90% of Qitai Hengtai at a price of 0 yuan, with plans for further investment in renewable energy projects [12][13]. - Suzhou Planning aims to acquire 80% of Kunshan Development Zone Architectural Design Institute for 831,720 yuan [18]. Regulatory and Compliance Issues - Haohai Biotechnology's controlling shareholder received an administrative penalty notice from the CSRC for suspected insider trading, although it is stated that this will not significantly impact the company's operations [7]. - Yunding Technology received a warning letter from the Shandong Securities Regulatory Bureau for inaccurate financial disclosures in its 2015 annual report [8]. Performance and Forecasts - Brothers Technology expects a net profit of 100 million to 115 million yuan for the first three quarters of 2025, representing a year-on-year increase of 207.32% to 253.42%, driven by rising prices of certain vitamin products and improved production efficiency [21]. Strategic Partnerships and Contracts - Jiuzhou Yiqu signed a strategic cooperation agreement with China Electric Power Construction Group Chengdu Survey and Design Institute to enhance collaboration in the rail transit sector [22]. - Luxiao Technology's subsidiary signed a strategic cooperation agreement to develop AI service robots for the US and European markets, aiming to sell at least 1 million units by 2026-2028 [23]. - China Shipbuilding Technology signed a green methanol sales contract worth approximately 40 million USD per year, with potential increases based on customer demand [24]. Stock Transactions and Shareholder Actions - Several companies, including Maidi Technology and Xin Hua Co., announced plans for shareholders to reduce their stakes, with reductions ranging from 1.7% to 3% of total shares [29][30][31][34][35].

Major Events - Angli Education plans to sell 100% equity of Kensington Park School Limited for £80,000 (approximately 760,100 RMB) to Hong Kong KS Education Group Limited to alleviate operational difficulties and reduce financial impact [1] Regulatory Actions - Haohai Biological's controlling shareholder, Jiang Wei, received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for suspected insider trading, which does not impact the company's daily operations or finances [2] - Yunding Technology received a warning letter from the Shandong Securities Regulatory Bureau for inaccurate information disclosure in its 2015 annual report, involving former executives who are now subject to administrative measures [3] Corporate Actions - Yaoshi Technology announced that the last day for conversion of Yaoshi convertible bonds is September 17, after which unconverted bonds will be forcibly redeemed at 100.62 RMB per bond, potentially leading to investment losses for investors [4] - Kanghui Pharmaceutical intends to change its stock abbreviation from "Kanghui Pharmaceutical" to "Kanghui Co., Ltd." [5] Strategic Partnerships - Jiuzhou Yitu signed a strategic cooperation agreement with China Electric Power Construction Group Chengdu Survey and Design Institute to enhance collaboration in the rail transit sector [6] - Luxiao Technology's subsidiary signed a strategic cooperation agreement to jointly develop AI service robots for the U.S. and European markets, aiming to sell at least 1 million units between 2026 and 2028 [6] - China Shipbuilding Technology signed a green methanol sales contract worth approximately $40 million per year, with potential increases based on customer demand, starting supply in 2028 [6] - Haon Automotive received a product designation notice for ADAS perception systems and radar systems, estimating total revenue of approximately 2.477 billion RMB over a 5-year project lifecycle, with mass production expected to start in April 2026 [6] Shareholding Changes - Medi Technology's shareholder, Weng Kang, plans to reduce his stake by up to 1.7% of the company's total shares, while another shareholder, Wu Di, intends to reduce his holdings by up to 0.0047% [7] - Xinhua Co., Ltd.'s director, Fang Junwei, plans to reduce his holdings by up to 75,200 shares, representing no more than 0.039% of the company's total shares [7]

Core Viewpoint - Kanghui Pharmaceutical (603139) announced a change in its stock name from "Kanghui Pharmaceutical" to "Kanghui Co., Ltd." to align with its long-term development plan, aiming for clearer market understanding and better reflection of its core value and development direction [1] Summary by Relevant Sections - **Company Name Change** - The new stock name is intended to be more concise and clear, retaining the core brand "Kanghui" while adding "Co., Ltd." to enhance market comprehension [1] - **Impact on Business Operations** - The company stated that this name change will not have a significant impact on its current operating performance, and there are no major changes in its main business [1] - **Regulatory Compliance** - The name change complies with relevant laws and regulations, including the Company Law and Securities Law, as well as the company's articles of association [1]

格隆汇9月16日丨康惠制药（维权）(603139.SH)公布，公司会议审议通过了《关于变更公司证券简称的 议案》，公司董事会同意将公司证券简称由"康惠制药"变更为"康惠股份"，公司证券代码"603139"保持 不变。 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-060 陕西康惠制药股份有限公司 关于拟变更证券简称的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、公司董事会审议变更证券简称的情况 陕西康惠制药股份有限公司董事会 特此公告。 二、公司证券简称变更的原因 根据公司长期发展规划，公司拟将证券简称由"康惠制药"变更为"康惠股 变更后的股票证券简称：康惠股份， 股票证券代码"603139"保持不变。 本次证券简称变更事项以上海证券交易所最终核准为准，公司将根据变更进展 情况及时履行信息披露义务，敬请投资者注意投资风险。 份"，新证券简称简洁清晰，在保留"康惠"这一核心品牌标识的同时，新增"股 份"二字有助于市场更直观理解公司发展定位，有助于投资者准确把握公司核心 价值与发展方向。 本次变更公司证券简称不会对公司目前的经营业绩产生重大影响，公司主营 业务未发生重大变化，不存在利用变更证券简称影响公司股价、误导投资者的情 形，本次变更符合公司实际情况与经营发展需要，符合《公司法》《证券法》等相 ...

Group 1 - The company, Kanghui Pharmaceutical, announced a change in its stock abbreviation from "Kanghui Pharmaceutical" to "Kanghui Co., Ltd." This change aims to provide a clearer and more concise representation of the company in the market [1] - The new abbreviation retains the core brand identifier "Kanghui" while adding "Co., Ltd." to help investors better understand the company's development positioning [1] - This adjustment is expected to assist investors in accurately grasping the company's core value and development direction [1]